Arcellx Inc Hits 20-Day Low
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Should l Buy ACLX?
Source: 144
Arcellx Inc (ACLX.O) has experienced a significant decline of 4.51% in its stock price, hitting a 20-day low. This movement reflects the company's recent struggles in the market.
The broader market is currently trading sideways, with major benchmarks showing mixed signals and a lack of clear direction. Despite the overall market being up by approximately 0.60%, Arcellx's performance stands out negatively.
Investors are closely monitoring the stock as it approaches critical support levels. The technical indicators suggest that further declines could be possible if the stock fails to recover from this low.
Market analysts suggest that the lack of relevant news may indicate that technical factors are primarily driving the stock's movement, rather than any specific company-related news.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACLX
Wall Street analysts forecast ACLX stock price to fall
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 113.790
Low
100.00
Averages
113.14
High
130.00
Current: 113.790
Low
100.00
Averages
113.14
High
130.00
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcellx Executive Sells $10.24 Million in Shares Amid Acquisition
- Executive Stock Sale: Rami Elghandour, President of Arcellx, sold 89,916 shares for approximately $10.24 million on February 27, 2026, indicating a potential shift in confidence despite retaining 276,051 shares directly and 416,500 shares indirectly.
- Sale Size Comparison: This sale is significantly larger than Elghandour's historical median sell size of 38,300 shares since January 2025, suggesting he may be adjusting his portfolio or adopting a cautious outlook on the company's future.
- Market Performance and Acquisition Dynamics: While Arcellx's stock has surged 75.55% over the past year, the company announced its acquisition by Gilead Sciences for approximately $7.8 billion, with a purchase price of $115 per share, indicating an impending delisting of the stock.
- Clinical Progress and Future Potential: Arcellx has recently achieved a breakthrough in its multiple myeloma treatment, advancing to Phase 2 development, and if its blood cancer immunotherapy receives FDA approval, it could generate significant revenue, yet the approaching merger introduces uncertainty for investors.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Kennedy-Wilson Holdings, Inc. (NYSE:KW) by a consortium led by William McMorrow, with shareholders expected to receive $10.90 per share in cash, highlighting the firm's commitment to shareholder rights.
- Masimo Corporation Transaction: Masimo Corporation (NASDAQ:MASI) has reached an acquisition agreement with Danaher Corporation, with shareholders set to receive $180.00 per share in cash, indicating strong market confidence in the company's valuation.
- Arcellx Acquisition: Arcellx, Inc. (NASDAQ:ACLX) is being acquired by Gilead Sciences, Inc., with shareholders expected to receive $115.00 per share in cash plus a contingent value right of $5.00 per share, which incentivizes shareholders to focus on the company's future milestones.
- Veris Residential Deal: Veris Residential, Inc. (NYSE:VRE) is set to be acquired by an investor consortium led by Affinius Capital, with shareholders expected to receive $19.00 per share in cash, enhancing the company's competitive position in the real estate market.
See More
ARCELLX INC: UBS Downgrades Rating to Neutral from Buy
Company Overview: ArcellX Inc. is a biotechnology company focused on developing innovative therapies and solutions in the healthcare sector.
Recent Developments: The company has made significant advancements in its research and product offerings, particularly in the area of neutralizing antibodies.
Market Impact: ArcellX's innovations are expected to have a substantial impact on the market, potentially improving treatment options for various diseases.
Future Prospects: The company is poised for growth, with ongoing research and development efforts aimed at expanding its product pipeline and market reach.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these adjustments to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to short-term volatility in the stocks involved, and investors should consider these changes as a reference for buying or selling, thereby affecting overall market sentiment.
- Investor Decision Impact: When considering purchasing DG stock, analysts' opinions will serve as a crucial reference for investors, especially in the current market environment where such insights could significantly affect the stock's future performance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions and expectations regarding these firms.
- Market Impact: These rating changes could influence investor decisions, particularly among those considering purchasing NVO stock, as analysts' opinions will serve as a crucial reference point.
- Source of Updates: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and analysis.
- Investment Advice Disclaimer: Benzinga reminds investors that it does not provide investment advice, and all information is for reference only, urging investors to assess risks independently.
See More
Investigation into Arcellx's Proposed Sale to Gilead Sciences
- Transaction Overview: Arcellx (NasdaqGS: ACLX) is proposed to be sold to Gilead Sciences (NasdaqGS: GILD) for $115 per share in cash plus a contingent value right of $5 per share, raising concerns about the company's valuation.
- Legal Investigation Initiated: Former Louisiana Attorney General Charles C. Foti and his law firm Kahn Swick & Foti, LLC are investigating whether the terms of the deal are adequate, particularly regarding the potential undervaluation of Arcellx.
- Shareholder Rights Emphasis: KSF encourages shareholders who believe the transaction undervalues the company or wish to discuss their legal rights to reach out, highlighting the importance of shareholder interests in the process.
- Urgency Reminder: As the transaction is structured as a tender offer, time may be of the essence, underscoring the need for shareholders to act swiftly to protect their interests.
See More
Arcellx Executive Sells $10.24 Million in Shares Amid Acquisition
- Executive Stock Sale: Rami Elghandour, President of Arcellx, sold 89,916 shares for approximately $10.24 million on February 27, 2026, indicating a potential shift in confidence despite retaining 276,051 shares directly and 416,500 shares indirectly.
- Sale Size Comparison: This sale is significantly larger than Elghandour's historical median sell size of 38,300 shares since January 2025, suggesting he may be adjusting his portfolio or adopting a cautious outlook on the company's future.
- Market Performance and Acquisition Dynamics: While Arcellx's stock has surged 75.55% over the past year, the company announced its acquisition by Gilead Sciences for approximately $7.8 billion, with a purchase price of $115 per share, indicating an impending delisting of the stock.
- Clinical Progress and Future Potential: Arcellx has recently achieved a breakthrough in its multiple myeloma treatment, advancing to Phase 2 development, and if its blood cancer immunotherapy receives FDA approval, it could generate significant revenue, yet the approaching merger introduces uncertainty for investors.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Kennedy-Wilson Holdings, Inc. (NYSE:KW) by a consortium led by William McMorrow, with shareholders expected to receive $10.90 per share in cash, highlighting the firm's commitment to shareholder rights.
- Masimo Corporation Transaction: Masimo Corporation (NASDAQ:MASI) has reached an acquisition agreement with Danaher Corporation, with shareholders set to receive $180.00 per share in cash, indicating strong market confidence in the company's valuation.
- Arcellx Acquisition: Arcellx, Inc. (NASDAQ:ACLX) is being acquired by Gilead Sciences, Inc., with shareholders expected to receive $115.00 per share in cash plus a contingent value right of $5.00 per share, which incentivizes shareholders to focus on the company's future milestones.
- Veris Residential Deal: Veris Residential, Inc. (NYSE:VRE) is set to be acquired by an investor consortium led by Affinius Capital, with shareholders expected to receive $19.00 per share in cash, enhancing the company's competitive position in the real estate market.
See More
ARCELLX INC: UBS Downgrades Rating to Neutral from Buy
Company Overview: ArcellX Inc. is a biotechnology company focused on developing innovative therapies and solutions in the healthcare sector.
Recent Developments: The company has made significant advancements in its research and product offerings, particularly in the area of neutralizing antibodies.
Market Impact: ArcellX's innovations are expected to have a substantial impact on the market, potentially improving treatment options for various diseases.
Future Prospects: The company is poised for growth, with ongoing research and development efforts aimed at expanding its product pipeline and market reach.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these adjustments to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to short-term volatility in the stocks involved, and investors should consider these changes as a reference for buying or selling, thereby affecting overall market sentiment.
- Investor Decision Impact: When considering purchasing DG stock, analysts' opinions will serve as a crucial reference for investors, especially in the current market environment where such insights could significantly affect the stock's future performance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions and expectations regarding these firms.
- Market Impact: These rating changes could influence investor decisions, particularly among those considering purchasing NVO stock, as analysts' opinions will serve as a crucial reference point.
- Source of Updates: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and analysis.
- Investment Advice Disclaimer: Benzinga reminds investors that it does not provide investment advice, and all information is for reference only, urging investors to assess risks independently.
See More
Investigation into Arcellx's Proposed Sale to Gilead Sciences
- Transaction Overview: Arcellx (NasdaqGS: ACLX) is proposed to be sold to Gilead Sciences (NasdaqGS: GILD) for $115 per share in cash plus a contingent value right of $5 per share, raising concerns about the company's valuation.
- Legal Investigation Initiated: Former Louisiana Attorney General Charles C. Foti and his law firm Kahn Swick & Foti, LLC are investigating whether the terms of the deal are adequate, particularly regarding the potential undervaluation of Arcellx.
- Shareholder Rights Emphasis: KSF encourages shareholders who believe the transaction undervalues the company or wish to discuss their legal rights to reach out, highlighting the importance of shareholder interests in the process.
- Urgency Reminder: As the transaction is structured as a tender offer, time may be of the essence, underscoring the need for shareholders to act swiftly to protect their interests.
See More
